Here are 1-3 brief analogies for Solventum (SOLV):

• A diversified medical supplies and dental products company, similar to a combination of Becton, Dickinson and Company (BD) for medical consumables and Dentsply Sirona for dental solutions.

• A comprehensive healthcare solutions provider, akin to a blend of Becton, Dickinson and Company (BD) for medical supplies and Oracle Health (formerly Cerner) for healthcare information systems.

• Medical & Surgical Solutions: Encompasses advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.
• Dental & Orthodontic Products: Includes a comprehensive suite of dental and orthodontic products such as brackets, aligners, restorative cements, and bonding agents.
• Health Information Systems: Provides software solutions for computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms.
• Purification & Filtration Technologies: Offers various purification and filtration products including filters, purifiers, cartridges, and membranes.

Solventum (SOLV) primarily sells its products and solutions to other companies and organizations rather than directly to individuals. As is common for diversified B2B healthcare companies, specific major customer companies are generally not publicly disclosed by Solventum.

However, based on the company's segments and product offerings described, its major customer categories include:

• Hospitals and Healthcare Systems: This category encompasses a wide range of medical facilities, including acute care hospitals, ambulatory surgery centers, and large integrated healthcare networks. These customers utilize Solventum's Medsurg products (such as advanced wound care, I.V. site management, surgical supplies) and Health Information Systems software solutions (like computer-assisted physician documentation and coding automation).
• Dental and Orthodontic Practices: This includes individual dental offices, orthodontic clinics, and group practices that purchase Solventum's comprehensive suite of dental and orthodontic products, such as brackets, aligners, restorative cements, and bonding agents.
• Life Sciences and Industrial Companies: This segment primarily serves the Purification and Filtration division. Customers in this category include pharmaceutical companies, biotechnology firms, food and beverage manufacturers, and other industrial clients that require specialized filtration and purification technologies for their processes.

Bryan Hanson, Chief Executive Officer

Bryan Hanson became CEO of Solventum in September 2023 and a Board Director in April 2024. He has over 33 years of experience in the global medical device industry. Prior to Solventum, he served as President and CEO of Zimmer Biomet from 2017 to 2023, where he led a transformation resulting in positive market share growth and cultural changes. He was also Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group, overseeing an approximately $9 billion business. Before Medtronic, he held various executive roles at Covidien, including Group President of its Medical Devices business and Surgical Solutions Group President. He was involved in Covidien spinning out of Tyco and Medtronic's acquisition of Covidien, playing a key role in that integration. He also led large divestitures, such as Medtronic selling its medical supplies business to Cardinal Health.

Wayde McMillan, Executive Vice President and Chief Financial Officer

Wayde McMillan is recognized for his finance expertise, deep understanding of the medtech industry, and ability to build strong teams. He brings over 25 years of experience in finance, driving profitable growth in dynamic environments for leading global and innovative companies. As CFO of Solventum, he focuses on the company's mission, positioning Solventum for long-term success, and creating long-term value for shareholders. Prior to Solventum, he served as Vice President of Global Manufacturing at Covidien.

Heather Knight, Chief Commercial Officer

Heather Knight is a strategic and people-first MedTech leader who excels at building high-performing teams. As Chief Commercial Officer at Solventum, she oversees global commercial and R&D operations across the MedSurg, Dental Solutions, and Health Information Systems segments. Her focus is on accelerating growth through coordinated execution, market development, and innovation. She has over 30 years of experience in the healthcare industry, including leadership roles in general management, upstream innovation, and commercial strategy at Baxter, Medtronic, Covidien, Tyco Healthcare, and Kendall.

Marcela Kirberger, Chief Corporate and Legal Affairs Officer and Corporate Secretary

Marcela Kirberger is a global legal, corporate affairs, and business leader with broad international experience in healthcare and life sciences. As Solventum's Chief Corporate and Legal Affairs Officer and Corporate Secretary, she leads the legal, government affairs, global security, and Sustainability teams, and also oversees communications, brand, and commercial marketing functions. She is responsible for setting the strategic direction for these areas, the company's global healthcare compliance program, and commercial legal and intellectual property matters. Before joining Solventum, Marcela served as General Counsel.

Rachel Ellingson, Chief Strategy & Corporate Development Officer

Rachel Ellingson is a seasoned healthcare executive and former investment banker with over 30 years of experience. She is recognized for her strategy and active portfolio management expertise and her ability to build strong, high-impact teams. She brings significant leadership experience, having led strategy, M&A, divestiture execution, investor relations, and communications in the medtech industry. At Solventum, she focuses on setting the company's strategic direction, portfolio transformation roadmap, and executing inorganic actions to drive long-term growth.

1. Reliance on 3M and operational transition challenges: Solventum's separation from 3M creates significant risks related to its ongoing reliance on its former parent for certain chemical materials and inputs, IT infrastructure, and other transition services. While agreements are in place, there's a risk of supply disruptions, less favorable pricing terms, and operational inefficiencies during the period of transition. The company also faces substantial costs and logistical challenges associated with rebranding its products away from the 3M logo by 2027.
2. Intense Competition: Solventum operates in highly competitive markets across all its segments, including Medsurg, Dental Solutions, and Health Information Systems. The company faces stiff competition from established global players, specialized niche providers, and emerging disruptive technologies. This intense competitive environment can lead to pricing pressure, impact market share, and necessitate continuous innovation to maintain and grow its position.
3. Litigation and Regulatory Risks, notably PFAS: As a healthcare company, Solventum is exposed to a highly regulated environment, including legal compliance risks related to antitrust, anti-bribery, environmental laws, privacy laws, and product liability. Specifically, while 3M retained most liabilities regarding PFAS (per- and polyfluoroalkyl substances) manufacturing, Solventum could still face future litigation or regulation related to its continued use of PFAS-containing materials manufactured by third parties beyond 2025, when 3M plans to discontinue manufacturing PFAS chemicals. The indemnification from 3M for manufacturing-related PFAS claims is limited until January 1, 2026.

The rapid advancement and integration of generative artificial intelligence (AI) models present a clear emerging threat to Solventum's Health Information Systems segment. This segment specializes in software solutions for computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization. Generative AI has the potential to significantly automate and optimize these processes, offering more efficient, accurate, and potentially lower-cost alternatives than existing proprietary software solutions. New entrants or existing large tech companies leveraging advanced AI could disrupt the market by offering superior or more seamlessly integrated AI-native platforms for healthcare information management, thereby reducing the reliance on or demand for Solventum's current offerings.

Solventum Corporation (NYSE: SOLV) operates in several key healthcare markets with significant addressable opportunities globally.

Overall Addressable Market

Solventum operates within a substantial global addressable market estimated at approximately $93 billion, which is projected to expand at an annual rate of 4-6% through 2026.

Market Sizes by Segment

Medsurg

The Medsurg segment includes solutions such as advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The advanced wound care market is a key component within this segment.

• Advanced Wound Care: The global advanced wound care market size was estimated at between USD 11.82 billion and USD 16.33 billion in 2025. It is projected to grow to a range of USD 18.91 billion to USD 60.68 billion by 2034/2035, with various sources citing CAGRs between 4.81% and 15.70%. North America accounted for approximately 47% of the revenue share in this market in 2024.

Dental Solutions

The Dental Solutions segment provides dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. Key addressable markets include dental prosthetics, orthodontic supplies, and restorative dentistry.

• Dental Prosthetics: The global dental prosthetics market size was estimated to be between USD 7.53 billion and USD 13.28 billion in 2024/2025. It is projected to reach between USD 13.9 billion and USD 30.27 billion by 2033/2035, with CAGRs ranging from 5.72% to 9.7%. North America held the largest share of this market, approximately 38% to 39.7%, in 2024/2025.
• Orthodontic Supplies: The global orthodontic supplies market size was estimated to be between USD 7.17 billion and USD 17.65 billion in 2025, with some sources placing the 2024 size at USD 8.45 billion to USD 9.18 million. It is projected to reach between USD 10.96 billion and USD 104.01 billion by 2030/2034/2035, with CAGRs varying from 8.9% to 21.85%. The orthodontic consumables market specifically was estimated at USD 3.0 billion in 2024, projected to reach USD 4.03 billion by 2030. North America dominated the orthodontic supplies market, holding approximately 40% to 43.37% market share in 2024/2025.
• Restorative Dentistry: The global restorative dentistry market size was estimated to be between USD 22.4 billion and USD 26.04 billion in 2024/2025/2026. It is projected to reach between USD 34.8 billion and USD 48.93 billion by 2030/2034, with CAGRs ranging from 7.7% to 7.94%. North America held the largest share in 2024, accounting for approximately 40.2% to 40.5% of the revenue.

Health Information Systems

This segment provides software solutions including computer-assisted physician documentation, coding automation, speech recognition, and data visualization platforms. This is part of the broader Healthcare IT market.

• Healthcare IT / Health Information Systems: The global healthcare IT market size was estimated to be between USD 354.04 billion and USD 866.48 billion in 2025, with some sources stating USD 370 billion to USD 588.39 billion in 2024/2025. It is projected to reach between USD 961.26 billion and USD 2,864.39 billion by 2030/2033/2034/2035, with CAGRs varying from 9.8% to 16.65%. North America consistently held the largest market share, ranging from approximately 43.23% to 51.54% in 2024/2025.

Purification and Filtration

The Purification and Filtration segment offers various purification and filtration technologies. Solventum announced in February 2025 its decision to divest its Purification & Filtration business, excluding the drinking water filtration segment.

• Medical Filtration: The global medical filtration market size was valued at approximately USD 6.26 billion to USD 6.29 billion in 2024. It is projected to reach between USD 9.35 billion and USD 22.54 billion by 2030/2032/2034, with CAGRs between 6.7% and 7.94%. North America leads this market.
• Filtration in Biologics: The global filtration in biologics market size was valued at USD 8.44 billion in 2025 and is anticipated to reach USD 29.01 billion by 2035, growing at a CAGR of 13.14% from 2026 to 2035. North America was dominant with a 46.9% revenue share in 2024.
• Industrial Filtration: The global industrial filtration market size was estimated to be between USD 36.03 billion and USD 43.38 billion in 2024/2025. It is projected to reach between USD 53.81 billion and USD 68.46 billion by 2033/2034, with CAGRs between 4.6% and 5.20%. North America dominated the global market with the largest market share, approximately 41%, in 2024.

For Solventum (SOLV), the following are expected drivers of future revenue growth over the next 2-3 years:

1. Strategic Acquisitions and Portfolio Optimization: Solventum anticipates revenue growth through strategic acquisitions, such as the recent acquisition of Acera Surgical, which is expected to contribute meaningfully to reported growth by opening doors to the fast-growth synthetic tissue market. The company emphasizes that portfolio optimization, including both acquisitions and divestitures, remains a key lever for value creation.
2. New Product Innovation and Enhanced Commercial Execution: A revitalized innovation process and a pipeline of nearly 20 new product launches over two years are expected to drive future revenue. This is coupled with ongoing sales force optimization and commercial improvements, which have already contributed to increased organic sales growth. Targeted investments in innovation and specialized sales teams are also cited as growth catalysts.
3. Targeted Growth in Key Business Segments: Solventum expects continued strong performance in specific segments and product categories. This includes advanced wound care, bolstered by innovations and the Acera acquisition; growth in Dental Solutions, particularly from core restoratives and improved back-order recovery; and momentum in Health Information Systems through revenue cycle management software solutions, autonomous coding, and AI-driven technologies.

Share Repurchases

• Solventum's Board of Directors approved a share repurchase program authorizing the company to purchase up to $1 billion of its outstanding common stock on November 20, 2025.
• The company expects to begin repurchasing shares in 2026.
• The share repurchase program has no time limit and may be suspended or discontinued at any time.

Share Issuance

• Solventum was spun off from 3M Company and began regular-way trading on April 1, 2024.
• 3M distributed 80.1% of Solventum's outstanding common stock to its shareholders, with one share of Solventum common stock received for every four shares of 3M common stock held.
• 3M retained 19.9% of the outstanding shares of Solventum common stock, which it intends to monetize within five years following the spin-off.

Outbound Investments

• Solventum completed the acquisition of Acera Surgical, a privately held bioscience company focused on regenerative wound care, for an upfront cash payment of $725 million and up to $125 million in contingent cash payments on December 23, 2025. The agreement was announced on November 20, 2025.
• The company completed the sale of its Purification & Filtration business to Thermo Fisher Scientific Inc. for $4.0 billion in cash on September 2, 2025.
• Net proceeds of $3.4 billion from the sale of the Purification & Filtration business were primarily used to pay down outstanding debt.

Capital Expenditures

• Solventum reported generating $805 million in free cash flow for the full year 2024.
• For 2026, the company introduced guidance for free cash flow of approximately $200 million.
• Capital allocation is focused on accelerating sustainable growth, pursuing targeted tuck-in mergers and acquisitions, and boosting innovation through programs like "transform for the future."